EMA Authorised: Opatanol (olopatadine hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Opatanol (olopatadine hydrochloride) for allergic conjunctivitis, with Novartis Europharm Limited as the marketing authorisation holder. The deci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Opatanol (olopatadine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Conjunctivitis, Allergic. MAH: Novartis Europharm Limited. Decision date: 21/01/2026